You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm generated $56.5 million in revenue compared to $37.4 million in Q3 2018, and beat the consensus Wall Street estimate of $55.0 million
The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The company continues to move toward its planned merger with German diagnostics firm Curetis, which is expected to close early next year.
The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
Opko logged $181.1 million in revenues from services, $26.2 million in revenue from products, and $21.5 million from licensing and intellectual property.
The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.
For fiscal 2020, BD provided guidance for revenue growth in the 4 to 4.5 percent range, or 5 to 5.5 percent on a currency-neutral basis.